Introduction {#sec1}
============

The incidence and mortality of human cancer are rapidly increasing, with an estimation of 18.1 million new cases and 9.6 million deaths in 2018 worldwide \[[@B1]\]. It is expected to be the leading cause of death and the single greatest threat to life expectancy in the 21st century \[[@B2]\]. Several environmental factors are revealed to play a role in carcinogenesis, including air pollutants, alcoholism, and virus infection \[[@B3],[@B4]\]. Smoking is estimated to account for more than 30% of all cancer deaths and 90% of lung cancer (LC) deaths, and approximately 62% of all recently diagnosed cancer patients are reported as smokers, which is becoming the most prominent risk factor for human cancer \[[@B5]\].

Besides environmental risk factors, genetic predisposition is also crucial for occurrence and development of cancer \[[@B6]\]. Researches have uncovered many candidate genes associated with tumorigenesis, such as DNA damage checkpoint genes (DDCGs). As a famous member of DDCG, *ataxia telangiectasia mutated* (*ATM*) encodes a serine/threonie protein kinase to play a major role in cell cycle checkpoints and DNA repair initiation by phosphorylating some key factors (e.g. p53), which is frequently mutated in human cancers \[[@B7],[@B9]\]. *ATM* rs189037 (G\>A), located at the 5′UTR of its promoter, is an important variant reportedly involving susceptibility to several cancers, but results remain inconclusive \[[@B10]\].

Some meta-analyses have made efforts to evaluate the role of *ATM* rs189037 in cancer risk. An early one was performed by Kang et al. (2014) \[[@B17]\], which only included one case--control study about rs189037. Then, Bhowmik et al. (2015) \[[@B18]\] and Yan et al. (2017) \[[@B19]\] conducted such analyses respectively focusing on specific cancer types. The latest meta-analysis was published by Zhao et al. (2019) \[[@B20]\], which explored the association between rs189037 and all cancer risk. However, all these meta-analyses did not consider effects of smoking, a most important environmental risk factor affecting most types of cancer. Additionally, they pooled results simply based on genotype information, rather than using confounder-adjusted odds ratio (OR), which possibly induced some bias from original studies. Therefore, we carried out this updated meta-analysis, aiming to use more refined data to clarify the effects of *ATM* rs189037 on cancer risk stratified by smoking status.

Materials and methods {#sec2}
=====================

This meta-analysis was carried out according to the statement of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@B21]\].

Literature search and eligibility criteria {#sec2-1}
------------------------------------------

Multiple databases including PubMed, Web of Science, Embase, and CNKI were searched for available relevant studies, without any restriction (updated till January 2019). The search items were used as follows: 'ATM', 'polymorphism', 'variant', 'cancer', 'smoking', 'cigarette' and 'rs189037'. We also performed manual search by reviewing the reference lists of identified publications for potentially relevant studies.

A study was considered eligible if it met all the following criteria: (i) it was a case--control study to investigate the association between *ATM* rs189037 and cancer risk; (ii) it reported the OR and 95% confidence interval (CI), or provided allele frequency and/or genotype distribution of *ATM* rs189037 in cases and controls; and (iii) it evaluated the effects of *ATM* rs189037 on cancer risk stratified by smoking status. If authors published multiple articles based on the same or overlapping datasets, we chose the study with the largest sample size. Exclusion criteria were as follows: (i) review, meta-analysis, comment, conference abstract, or experimental research; and (ii) articles without healthy controls or with duplication of earlier studies. Two independent authors conducted the literature search and study selection and discrepancy was solved by discussion.

Data extraction and quality evaluation {#sec2-2}
--------------------------------------

Two authors independently extracted the items from each included study, including the first author's name, publication year, cancer type, country, ethnicity, the number of cases and controls, genotyping methods, and proportion of males and smokers. In addition, multivariate-adjusted OR and 95% CI, genotype distribution, and allele frequency based on smoking status were also recorded from these eligible studies.

The quality of each included study was evaluated by the Newcastle--Ottawa scale (NOS), with scores in a range from '0' to '9' \[[@B22]\]. Quality evaluation was not an exclusion criterion for eligible studies (Supplementary Table S1).

Statistical analysis {#sec2-3}
--------------------

The Hardy--Weinberg equilibrium was assessed in genotypes of controls by using a χ^2^ test. The strength of the association between *ATM* rs189037 and cancer risk was measured with OR and 95% CI. Multivariate-adjusted ORs and 95% CIs were preferentially extracted from included studies if available, otherwise unadjusted ORs and 95% CIs were calculated based on genotypes or allele frequencies. Cochran's Q test and *I^2^* statistic were used to evaluate the heterogeneity among studies, and *P*\<0.10 or *I^2^* \> 50 % indicates significant heterogeneity \[[@B23]\]. A random-effects model was applied to pool results under significant heterogeneity, otherwise a fixed-effects model was used \[[@B24]\]. Moreover, subgroup analysis was carried out to further explore more specific roles of *ATM* rs189037 in cancer risk. We conducted one-way sensitivity analysis to assess the stability of pooled results. In addition, we also examined publication bias by Begg's and Egger's tests \[[@B25],[@B26]\]. A two-sided *P*≤0.05 was considered as significant, unless otherwise specified. Our meta-analysis was performed by Stata 12.0 software (College Station, TX, U.S.A.).

Results {#sec3}
=======

Characteristics of included studies {#sec3-1}
-----------------------------------

Initially, we identified 202 records from a comprehensive search via different databases. After removing 116 duplicates, we also excluded 58 records by reviewing titles and abstracts due to not being original articles (e.g. review, meta-analysis, comment), and not related to cancer risk. Out of the remaining 28 records for full-text review, we further removed 21 studies based on the following reasons: (i) relevant to other variants of *ATM* but not rs189037; and (ii) providing insufficient genotype information of *ATM* rs189037 based on smoking status. Finally, a total of seven eligible studies were included for meta-analysis ([Figure 1](#F1){ref-type="fig"}) \[[@B10]\].

![A flowchart of literature search and study selection](bsr-39-bsr20191298-g1){#F1}

Characteristics of these studies are summarized in [Table 1](#T1){ref-type="table"}. All the subjects were East Asians from China. Overall, there were 2405 males (56.0%) and 1744 smokers (40.6%) in 4294 cancer patients, and were 2331 males (54.7%) and 1418 smokers (33.3%) in 4259 controls. Four studies focused on LC \[[@B11],[@B15]\], and the remaining studies focused on oral cancer (OC) \[[@B10]\], esophageal squamous cell carcinoma (ESCC) \[[@B14]\] and colorectal cancer (CRC) \[[@B16]\], respectively. All these studies had an NOS score ≥ 5. [Table 2](#T2){ref-type="table"} shows the genotype distribution and allele frequency of *ATM* rs189037 in smokers, non-smokers, and overall subjects.

###### Characteristics of included studies

  Study                Type   Country   Ethnicity     Cases/Controls   Male (case/control), *n* (%)   Smokers (case/control), *n* (%)   Genotyping method   NOS score
  -------------------- ------ --------- ------------- ---------------- ------------------------------ --------------------------------- ------------------- -----------
  Bau et al. (2010)    OC     China     East Asians   620/620          586 (94.5)/582 (93.9)          458 (73.9)/443 (71.5)             PCR-RFLP            5
  Lo et al. (2010)     LC     China     East Asians   730/730          384 (52.6)/384 (52.6)          268 (36.7)/268 (36.7)             MassARRAY           5
  Liu et al. (2014)    LC     China     East Asians   852/852          485 (56.9)/490 (57.5)          477 (66.0)/273 (32.0)             TaqMan assay        6
  Shen et al. (2014)   LC     China     East Asians   487/516          All females                    All non-smokers                   TaqMan assay        7
  Yu et al. (2015)     ESCC   China     East Asians   303/304          258 (85.1)/253 (83.2)          214 (70.60)/153 (50.3)            TaqMan assay        6
  Han et al. (2017)    LC     China     East Asians   181/181          61 (33.7)/61 (33.7)            All non-smokers                   MassARRAY           5
  Wang et al. (2018)   CRC    China     East Asians   1121/1056        631 (56.3)/561 (53.1)          327 (29.2)/281 (26.6)             TaqMan assay        6

Abbreviation: PCR-RFLP, polymerase chain reaction and restriction fragment length polymorphism.

###### Genotype distribution and allele frequency of *ATM* rs189037 stratified by smoking status

  Study                Smoking exposure        Genotype (GG/GA/AA)                          Minor allele frequency (A allele)            *P~HWE~*           
  -------------------- ----------------------- -------------------------------------------- -------------------------------------------- ---------- ------- -------
  Bau et al. (2010)    Overall                 181/277/162                                  239/285/96                                   48.47      38.47   0.470
                       Smokers                 337/121[^1^](#T2TFN1){ref-type="table-fn"}   374/69[^1^](#T2TFN1){ref-type="table-fn"}    \-         \-      \-
                       Non-smokers             121/41[^1^](#T2TFN1){ref-type="table-fn"}    150/27[^1^](#T2TFN1){ref-type="table-fn"}    \-         \-      \-
  Lo et al. (2010)     Overall                 238/345/145                                  239/354/124                                  43.61      41.98   0.717
                       Smokers                 103/122/42                                   82/131/49                                    38.58      43.70   0.794
                       Non-smokers             135/223/103                                  157/223/72                                   46.53      40.60   0.626
  Liu et al. (2014)    Overall                 217/435/200                                  264/434/154                                  49.00      43.54   0.293
                       Smokers                 120/249/108                                  87/129/57                                    48.74      44.51   0.473
                       Non-smokers             97/186/92                                    177/305/97                                   49.33      43.09   0.075
  Shen et al. (2014)   Overall (non-smokers)   148/240/99                                   152/272/92                                   44.97      44.19   0.119
  Yu et al. (2015)     Overall                 106/139/58                                   114/145/45                                   42.08      38.65   0.920
                       Smokers                 72/97/45                                     59/67/27                                     43.69      39.54   0.298
                       Non-smokers             34/42/13                                     55/78/18                                     38.20      37.75   0.223
  Han et al. (2017)    Overall (non-smokers)   56/83/39                                     54/92/32                                     45.22      43.82   0.507
  Wang et al. (2018)   Overall                 336/543/227                                  362/491/191                                  45.07      41.81   0.280
                       Smokers                 107/213[^2^](#T2TFN2){ref-type="table-fn"}   106/171[^2^](#T2TFN2){ref-type="table-fn"}   \-         \-      \-
                       Non-smokers             229/557[^2^](#T2TFN2){ref-type="table-fn"}   256/511[^2^](#T2TFN2){ref-type="table-fn"}   \-         \-      \-

indicates the number of (GG+GA)/AA.

indicates the number of GG/(GA+AA).

Association between *ATM* rs189037 and cancer risk stratified by smoking status {#sec3-2}
-------------------------------------------------------------------------------

The allelic, dominant, recessive, and codominant models were applied to pool results ([Table 3](#T3){ref-type="table"}). Overall, *ATM* rs189037 A allele exhibited a 1.17-fold increased risk of cancer compared with the G allele (OR = 1.17, 95% CI = 1.0--1.30). Other genetic models showed the same results. Analysis based on smoking status, we further found a consistent and significant association of *ATM* rs189037 with cancer risk in non-smokers (allelic model: OR = 1.16, 95% CI = 1.05--1.28; dominant model: OR = 1.43, 95% CI = 1.22--1.69; recessive model: OR = 1.14, 95% CI = 1.01--1.29; codominant AA vs GG model: OR = 1.40, 95% CI = 1.15--1.70; additive model: OR = 1.16, 95% CI = 1.06--1.28). Interesting, however, the association was not observed in smokers (all *P*\>0.05).

###### Meta-analysis for the association between ATM rs189037 and cancer risk stratified by smoking status

  Genetic model[^1^](#T3TFN1){ref-type="table-fn"}   Effect size   Heterogeneity           Publication bias                  
  -------------------------------------------------- ------------- ----------------------- ------------------ ------ ------- -------
  Allelic model                                                                                                              
    Overall                                          7             **1.17 (1.06--1.30)**   0.026              58.0   0.764   0.738
    Non-smokers                                      5             **1.16 (1.05--1.28)**   0.324              14.2   0.806   0.514
    Smokers                                          3             1.04 (0.81--1.34)       0.044              68.0   0.956   0.602
  Dominant model                                                                                                             
    Overall                                          7             **1.32 (1.19--1.47)**   0.130              39.2   0.548   0.780
    Non-smokers                                      6             **1.43 (1.22--1.69)**   0.642              0.0    0.707   0.894
    Smokers                                          4             1.24 (0.84--1.82)       0.013              72.1   0.734   0.403
  Recessive model                                                                                                            
    Overall                                          7             **1.19 (1.08--1.30)**   0.107              42.5   0.548   0.344
    Non-smokers                                      6             **1.14 (1.01--1.29)**   0.504              0.0    0.851   0.263
    Smokers                                          4             1.12 (0.83--1.50)       0.048              62.0   0.308   0.902
  Codominant model (AA vs. GG)                                                                                               
    Overall                                          7             **1.42 (1.18--1.70)**   0.077              47.4   0.881   0.727
    Non-smokers                                      5             **1.40 (1.15--1.70)**   0.433              0.0    1.000   0.608
    Smokers                                          3             1.12 (0.68--1.83)       0.064              63.6   0.602   0.983
  Codominant model (GA vs. GG)                                                                                               
    Overall                                          7             1.11 (1.00--1.22)       0.338              11.9   0.548   0.153
    Non-smokers                                      5             1.01 (0.86--1.18)       0.713              0.0    1.000   0.391
    Smokers                                          3             1.06 (0.72--1.57)       0.063              63.8   0.602   0.852
  Additive model                                                                                                             
    Overall                                          7             **1.17 (1.07--1.29)**   0.044              53.6   0.764   0.655
    Non-smokers                                      5             **1.16 (1.06--1.28)**   0.317              15.3   0.806   0.515
    Smokers                                          3             1.04 (0.81--1.34)       0.046              67.5   0.602   0.937

Allelic model refers to A allele vs. G allele; dominant model refers to AA+GA vs. GG; recessive model refers to AA vs. GG+GA.

Considering that smoking is the crucial pathogenic factor for LC, we further evaluated effects of *ATM* rs189037 on LC based on smoking status ([Figure 2](#F2){ref-type="fig"}). Overall, *ATM* rs189037 AA carriers had more risk of LC than wild-type carriers (OR = 1.33, 95% CI = 1.11--1.58). Specially, the association was more notable in non-smokers (OR = 1.41, 95% CI = 1.15--1.73). Also, we did not find any association of this variant with LC risk in smokers. In addition, individuals with GA genotype did not suffer more susceptibility to overall cancer or LC than those with GG genotype, no matter in smokers or in non-smokers (all *P*\>0.05).

![Forest plots of the association between ATM rs189037 and LC risk\
Forest plots for evaluation of the association between *ATM* rs189037 and LC risk under the codominant models of AA vs GG (**A**) and GA vs GG (**B**).](bsr-39-bsr20191298-g2){#F2}

Sensitivity analysis and publication bias {#sec3-3}
-----------------------------------------

To assess the stability of pooled results, we conducted one-way sensitivity analysis by excluding one study at a time. It demonstrated that our pooed results were quite stable in both non-smokers and smokers (Supplementary Figure S1). In addition, results from Begg's and Egger's tests showed that there was no obvious publication bias in our meta-analyses under all genetic models ([Table 3](#T3){ref-type="table"}).

Discussion {#sec4}
==========

In this meta-analysis, we have four findings as follows: (i) *ATM* rs189037 significantly increased the overall risk of cancer under most of genetic models; (ii) the risky role of *ATM* rs189037 was prominent in non-smokers, but not observed in smokers; (iii) results focusing on LC were consistent with results of overall cancer; and (iv) GA genotype carriers of *ATM* rs189037 appeared not to suffer more cancer risk than GG wild-type carriers, no matter in smokers or in non-smokers.

In agreement with previous meta-analyses \[[@B17]\], our work suggested that *ATM* rs189037 is a risky variant for cancer susceptibility, but we have some new highlights. First, we elucidated the association between this variant and cancer risk stratified by smoking status, and specially focused on LC. Results demonstrated different effects of *ATM* rs189037 in non-smokers and in smokers. Second, we pooled results by extracting multivariate-adjusted ORs and 95% CIs if available, greatly reducing confounder bias from original studies. Third, we performed a comprehensive literature and included a study ignored by previous meta-analyses \[[@B14]\].

Rs189037 (G\>A) is located at the promoter region of *ATM* gene, alleles of which may possibly have different binding affinities to transcription factors (e.g. AP-2α) or change *ATM* folding structure to affect its mRNA expression, and AA genotype was reported to show a lower *ATM* expression than GG genotype \[[@B16],[@B27],[@B28]\]. Reduced *ATM* expression may impair its normal function, lead to uncontrolled cell cycle, abnormal DNA repair and apoptosis, and finally increase the susceptibility to cancer. This could well explain our findings that individuals with *ATM* rs189037 suffer more cancer risk. Furthermore, our results demonstrated the association was significant in non-smokers rather than in smokers, no matter for overall cancer or for LC. As the most important risk factor for human cancer, smoking induces a serious of potential carcinogens to generate DNA damage and oxidative stress, resulting in gene mutations and genomic instability. Smoking-related cancers have a high mutational load and highly significant molecular heterogeneity \[[@B29]\]. Compared with non-smokers, smokers probably alert more gene pathways to remove those tobacco-induced DNA adducts and activate more antioxidant mechanisms to fight against smoking-related stress. Consistently, we identified obvious heterogeneity among included studies in smokers, whereas we observed a good homogeneity among studies in non-smokers, both for overall cancer and LC (all *P*~heterogeneity~\>0.10, *I^2^* \< 50%). These results suggest that smoking-related cancers has distinct molecular characteristics from non-smoking-related cancers. Supportively, a recent study revealed that LCr in smokers and in non-smokers showed quite different tumor immune microenvironments \[[@B30]\].

However, some limitations should be acknowledged here. First, only seven studies were eligible for inclusion in our study. The small number of studies possibly affected the conclusion's extrapolation to some extent. More studies are still needed to verify our results. Second, we did not evaluate the effects of this variant in other ethnic populations, since all included subjects were Chinese. At last, except for LC, number of studies focusing on other cancer is limited, so we could not explore its role based on subgroup analysis in other cancer types.

Conclusions {#sec5}
===========

Our study highlights that there is a significant association between *ATM* rs189037 and cancer risk in non-smokers, rather than in smokers. This association is prominent in LC. Our work not only provides a new insight into the pathogenic role of *ATM* variants in occurrence of cancer, but also supports the distinct molecular characteristics of cancers between smokers and non-smokers. More studies are still needed to verify our results in the future.
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